


## CARE PROTOCOL: Antiphospholipid Antibody Syndrome (APS)

Gestational age	Recommended intervention
<20 weeks gestation	<ul style="list-style-type: none"> <li>• Obtain consult with Maternal-Fetal Medicine.</li> <li>• Confirm GA/EDC.</li> <li>• Check blood pressure (BP) and determine need for treatment; if BP &gt;140/90, initiate antihypertensive therapy:               <ul style="list-style-type: none"> <li>– Labetalol – first-line medication choice.</li> <li>– Nifedipine – second-line medication choice.</li> </ul> </li> <li>• Obtain baseline results for:               <ul style="list-style-type: none"> <li>– 24-hour urine for total protein and serum creatinine.</li> <li>– Liver function tests (AST/ALT).</li> <li>– Platelet count.</li> </ul> </li> <li>• Initiate low-dose aspirin therapy as early as possible in pregnancy.</li> <li>• Initiate heparin prophylaxis with appropriate monitoring:               <ul style="list-style-type: none"> <li>– If NO history of VTE,                   <ul style="list-style-type: none"> <li>› Give either: heparin 7,500 units subcutaneous twice a day, or Lovenox 40 mg subcutaneous once a day.</li> <li>› Follow platelet count every 3 days x 2 weeks to rule out heparin-induced thrombocytopenia (HIT).</li> </ul> </li> <li>– If HISTORY of VTE,                   <ul style="list-style-type: none"> <li>› Initiate Lovenox 1 mg/kg subcutaneous twice a day.</li> <li>› Follow platelet count every 3 days x 2 weeks to rule out heparin-induced thrombocytopenia (HIT).</li> <li>› Adjust dose of Lovenox to achieve serial Anti-Factor Xa levels in the upper half of therapeutic range.</li> </ul> </li> </ul> </li> <li>• Initiate home BP monitoring and establish BP review every 2 to 4 weeks; instruct patient to call if readings are consistently &gt;140/90 mm Hg.</li> <li>• Review signs and symptoms of preeclampsia with the patient.</li> </ul>
20–28 weeks gestation	<ul style="list-style-type: none"> <li>• Perform ultrasound to assess fetal growth and AFI at 28–30 weeks GA.</li> <li>• Review BP and determine need to initiate or adjust antihypertensive therapy (see first- and second-line choices in row above); consider antenatal surveillance if hypertension or preeclampsia develops (see schedule in the row below).</li> <li>• If indications of preeclampsia, IUGR or fetal distress:               <ul style="list-style-type: none"> <li>– Admit for evaluation of maternal/fetal condition. Transfer to tertiary care center if appropriate NICU services are not available.</li> <li>– Give steroids. See PTL/PTB Medication Table on page 23.</li> <li>– Give magnesium sulfate. See PTL/PTB Medication Table on page 23.</li> </ul> </li> </ul>
29–32 weeks gestation	<ul style="list-style-type: none"> <li>• Review BP and determine need to initiate or adjust antihypertensive therapy (see first- and second-line choices in first row above).</li> <li>• Initiate antenatal surveillance (nonstress test, amniotic fluid assessment, and biophysical profile) per schedule below:               <ul style="list-style-type: none"> <li>– No hypertension, IUGR, or oligohydramnios – weekly at 32 weeks gestation.</li> <li>– Mild hypertension or preeclampsia – twice weekly at 32 weeks or at diagnosis.</li> <li>– Severe hypertension – twice weekly beginning at 28 weeks or at diagnosis.</li> </ul> </li> <li>• If indications of preeclampsia, IUGR or fetal distress:               <ul style="list-style-type: none"> <li>– Admit for evaluation of maternal/fetal condition. Transfer to tertiary care center if appropriate NICU services are not available.</li> <li>– Give steroids. See PTL/PTB Medication Table on page 23.</li> <li>– Give magnesium sulfate. See PTL/PTB Medication Table on page 23.</li> </ul> </li> </ul>
Delivery timing	<ul style="list-style-type: none"> <li>• Delivery will occur at &gt;37 weeks GA unless one of the following occurs:               <ul style="list-style-type: none"> <li>– Severe preeclampsia.</li> <li>– Nonreassuring results noted on antenatal surveillance abnormal NST, positive CST, BPP &lt;6 or abnormal UA Doppler.</li> <li>– Severe IUGR (&lt;10%) with oligohydramnios (AFI &lt;5 cm).</li> </ul> </li> </ul>
PATIENT EDUCATION MATERIALS 	<p>Intermountain fact sheets supporting this risk-specific protocol:</p> <ul style="list-style-type: none"> <li>• <a href="#">Anticoagulant Injections</a></li> <li>• <a href="#">Preeclampsia</a></li> <li>• <a href="#">How to Monitor Your Blood Pressure</a></li> <li>• <a href="#">BP Tracker</a></li> <li>• <a href="#">Fetal Testing (nonstress test, amniotic fluid assessment, and biophysical profile)</a></li> </ul> <p>Fact sheets available in English and Spanish. See page 25 for a list of all related resources, instructions for accessing them.</p>

### ✓ KEY ACTIONS for providers:

- Initiate ASA therapy before 12 weeks gestation.
- Initiate heparin prophylaxis before 12 weeks gestation.
- Follow delivery timing guidelines in this protocol.